ID | 56374 |
JaLCDOI | |
フルテキストURL | |
著者 |
Yagi, Takahito
Hepato-Biliary and Pancreatic Surgery, Okayama University Hospital
Takagi, Kosei
Hepato-Biliary and Pancreatic Surgery, Okayama University Hospital
Umeda, Yuzo
Hepato-Biliary and Pancreatic Surgery, Okayama University Hospital
Yoshida, Ryuichi
Hepato-Biliary and Pancreatic Surgery, Okayama University Hospital
Nobuoka, Daisuke
Hepato-Biliary and Pancreatic Surgery, Okayama University Hospital
Kuise, Takashi
Hepato-Biliary and Pancreatic Surgery, Okayama University Hospital
Fujiwara, Toshiyoshi
Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
|
抄録 | Living donor liver transplantation (LDLT) is the final therapeutic arm for pediatric end-stage liver diseases. Toward the goal of achieving further improvement in LDLT survival, we investigated factors affecting recipient survival. We evaluated the prognostic factors of 60 pediatric recipients (< 16 years old) who underwent LDLT between 1997 and 2015. In a univariate analysis, non-cholestatic (NCS) disease, graft/recipient body weight ratio, cold and warm ischemic times, and intraoperative blood loss were significant factors impacting survival. In a multivariate analysis, NCS disease was the only significant factor worsening survival (p=0.0021). One-and 5-year survival rates for the cholestatic disease (CS, n=43) and NCS (n=17) groups were 100% vs. 70.6% and 97.4% vs. 58.8% (p=0.004, log-rank). Intergroup comparisons revealed that CS was significantly associated with operation time, cold ischemia, hepatomegaly of the native liver, and portal plasty. These data suggest that a cirrhotic, swollen, artery-dominant liver did not increase graft size-related risks despite the surgical complexity of preceding operations. The NCS group’s poorer survival originated from recurrence of the primary disease and liver manifestation of systemic disease untreatable by transplantation. Improving the survival of pediatric recipients requires intensive efforts to prevent primary disease relapse and more rapid diagnoses to exclude contraindications from NCS disease.
|
キーワード | liver transplantation
living donor
pediatrics
prognostic factor
cholestatic disease
|
Amo Type | Original Article
|
出版物タイトル |
Acta Medica Okayama
|
発行日 | 2018-12
|
巻 | 72巻
|
号 | 6号
|
出版者 | Okayama University Medical School
|
開始ページ | 567
|
終了ページ | 576
|
ISSN | 0386-300X
|
NCID | AA00508441
|
資料タイプ |
学術雑誌論文
|
言語 |
英語
|
著作権者 | CopyrightⒸ 2018 by Okayama University Medical School
|
論文のバージョン | publisher
|
査読 |
有り
|
PubMed ID | |
NAID |